COPD News

Among patients with COPD, those receiving 6-week nicotinamide riboside, “a B3-like vitamin,” had significantly decreased lung inflammation, according to results published in Nature Aging.

Around 20% to 25% of individuals with rapidly declining FEV1/FVC trajectories experienced wheezing and usual phlegm/bronchitis as adolescents/young adults, according to results published in The Lancet Respiratory Medicine.

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers reported.

The ability to predict spirometry-defined COPD was significantly better when a modified lung function questionnaire score was used in combination with a COPD polygenic risk score, according to results published in JAMA.

The adjusted likelihood for an injurious fall in adults with COPD was elevated with a fall-risk increasing drug prescription, according to results published in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation.

The adjusted risk for COPD was elevated among adults who identified as regular cigarette smokers before age 15 years, according to results published in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation.

In 2022, chronic lower respiratory disease was the sixth highest cause of death in the U.S., according to results published in National Vital Statistics Reports.

Medicare beneficiaries with emphysema who received an endobronchial valve vs. lung volume reduction surgery faced elevated risk-adjusted odds for poor outcomes, according to data presented at the Society of Thoracic Surgeons Annual Meeting.

Among patients with COPD who experienced an exacerbation, the risk for cardiovascular events was highest in the following 2 weeks and stayed elevated more than 1 year after, according to study results.